ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Obituary: Ellen Tobin, Consultant, Championed Patients’ Needs;

January 10, 2003

NCAB Approves Grants For Action Plan On Breast Cancer

September 22, 1995

NCI Recruits Carl Barrett Of NIEHS To Direct Basic Sciences; Freedman named to NCAB.

March 31, 2000

Cell Phone Radiation Does Not Raise Child’s Risk of Tumors

August 26, 2011

In Brief: NCI’s Katz Named Director, Arthritis Institute; Hayden Promoted At Bristol-Myers Squibb

July 14, 1995

BRAF Inhibitor Shrank Tumors In Phase II Genentech Study

November 26, 2010